[Form 4] IPG PHOTONICS CORP Insider Trading Activity
Rhea-AI Filing Summary
Form 4 summary for IPG Photonics (IPGP): Eugene A. Scherbakov, a director and reported >10% owner, sold shares on 09/23/2025 under a pre-established Rule 10b5-1 trading plan. The Form 4 reports two sale transactions: 1,555 shares at a weighted-average price of $81.54 and 1,145 shares at a weighted-average price of $82.17. Following the sales the filing lists beneficial ownership amounts of 71,275 and 70,130 shares respectively. The filing was signed by an attorney-in-fact on 09/24/2025 and includes commitments to provide detailed per-price execution data upon request.
Positive
- Sales executed under a Rule 10b5-1 plan, indicating pre-arranged transactions and reduced likelihood of opportunistic trading
- Clear disclosure of weighted-average prices and ranges with an offer to provide per-price execution details upon request
- Form 4 filed and signed (via attorney-in-fact), demonstrating compliance with Section 16 reporting requirements
Negative
- Insider sold 2,700 shares (1,555 + 1,145), which reduces the reporting person’s direct holdings
- Filing does not state the total outstanding holdings percentage, so investors cannot assess the absolute size of the remaining stake from this form alone
Insights
TL;DR: A director and significant owner executed Rule 10b5-1 sales totaling 2,700 shares on 09/23/2025, at ~ $81.54–$82.17 per share.
The disclosure is routine in structure: sales were effected pursuant to a Rule 10b5-1 trading plan adopted 06/13/2025, which indicates pre-arranged execution rather than opportunistic timing. The filing provides weighted-average prices and affirms willingness to supply per-price execution details to regulators or holders. For investors, this is a transparent insider disposition rather than an unexplained immediate sale.
TL;DR: Insider sales reported under a documented 10b5-1 plan, with full Form 4 compliance and signature by attorney-in-fact.
The form shows compliance with Section 16 reporting obligations and inclusion of explanatory notes clarifying price ranges and the plan adoption date. The presence of an attorney-in-fact signature is standard when an agent executes filings. The filing does not disclose any derivative transactions or other changes in control.